Samuel J. Gesten - Aug 12, 2021 Form 4 Insider Report for STAAR SURGICAL CO (STAA)

Role
Chief Legal Officer
Signature
Samuel J. Gesten
Stock symbol
STAA
Transactions as of
Aug 12, 2021
Transactions value $
-$3,150,958
Form type
4
Date filed
8/13/2021, 04:22 PM
Next filing
Oct 5, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STAA Common Stock Options Exercise $108K +6.67K +15.66% $16.15 49.3K Aug 12, 2021 Direct
transaction STAA Common Stock Options Exercise $134K +4.5K +9.13% $29.80 53.7K Aug 12, 2021 Direct
transaction STAA Common Stock Options Exercise $409K +11.4K +21.14% $35.98 65.1K Aug 12, 2021 Direct
transaction STAA Common Stock Options Exercise $197K +7.16K +10.99% $27.53 72.3K Aug 12, 2021 Direct
transaction STAA Common Stock Sale -$4M -29.7K -41.07% $134.71 42.6K Aug 12, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STAA Common Stock Options Options Exercise $0 -6.67K -100% $0.00* 0 Aug 12, 2021 Common Stock 6.67K $16.15 Direct
transaction STAA Common Stock Options Options Exercise $0 -4.5K -100% $0.00* 0 Aug 12, 2021 Common Stock 4.5K $29.80 Direct
transaction STAA Common Stock Options Options Exercise $0 -11.4K -66.67% $0.00 5.68K Aug 12, 2021 Common Stock 11.4K $35.98 Direct F2
transaction STAA Common Stock Options Options Exercise $0 -7.16K -44.44% $0.00 8.95K Aug 12, 2021 Common Stock 7.16K $27.53 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.58 to $137.35 inclusive.
F2 The options granted become exercisable as follows: 1/3 on 3/14/2020 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 3/14/2022.
F3 The options granted become exercisable as follows: 1/3 on 3/20/2021 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 3/20/2023.

Remarks:

This Form 4 reflects a sale by Mr. Gesten of Common Stock of the Company pursuant to instructions contained in a pre-established Rule 10b5-1 plan.